90 likes | 177 Vues
Explore the impact of rosuvastatin on cardiovascular outcomes and lipid levels during a study period. Analyze baseline characteristics and adverse events. Examine cumulative incidence and trial outcomes based on study groups.
E N D
Baseline Characteristics of the Trial Participants, According to Study Group* - Part I PM Ridker, et al. N Engl J Med 2008;359:2195-207
Baseline Characteristics of the Trial Participants, According to Study Group* - Part II PM Ridker, et al. N Engl J Med 2008;359:2195-207
Lipid and High-Sensitivity C-Reactive Protein Levels during the Follow-up Period, According to Study Group* PM Ridker, et al. N Engl J Med 2008;359:2195-207
Outcomes According to Study Group PM Ridker, et al. N Engl J Med 2008;359:2195-207
Cumulative Incidence of Cardiovascular Events According to Study Group PM Ridker, et al. N Engl J Med 2008;359:2195-207
Effects of Rosuvastatin on the Primary End Point, According to Baseline Characteristics PM Ridker, et al. N Engl J Med 2008;359:2195-207
Monitored Adverse Events, Measured Laboratory Values, and Other Reported Events of Interest during the Follow-up Period* PM Ridker, et al. N Engl J Med 2008;359:2195-207
Trial schematic PM Ridker, et al. N Engl J Med 2008;359:2195-207 - Online Supplemental Appendix
Relationship of the proportional reduction in cardiovascular event rate and mean LDL cholesterol difference between treatment groups in published statin trials PM Ridker, et al. N Engl J Med 2008;359:2195-207 - Online Supplemental Appendix